JAZZ completed the acquisition of Actio Biosciences.
Jazz Pharmaceuticals plc（JAZZ）完成收购 Actio Biosciences。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
Iannone Robert sells $19.2M of JAZZIannone Robert 内部减持 爵士制药 (JAZZ) $19.2M
Insider Sale · August 31, 2026内部人减持 · 2026/8/31
JAZZ financing pricing: Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesJazz Pharmaceuticals plc（JAZZ）完成融资定价，规模 $1.1 Billion
Material Company Event · August 27, 2026公司公告 · 2026/8/27
JAZZ regulatory decision: U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaJazz Pharmaceuticals plc（JAZZ）的 产品 获美国 FDA 许可或批准
Material Company Event · August 25, 2026公司公告 · 2026/8/25
